The Royal Marsden Hospitals
Welcome,         Profile    Billing    Logout  
 9 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Popat, Sanjay
BEAT-meso, NCT03762018 / 2018-002180-25: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Active, not recruiting
3
401
Europe
Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Pleural Mesothelioma Malignant Advanced
09/23
03/25
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients with Early-stage, Operable, Non-small Cell Lung Cancer.

Recruiting
3
290
Europe, RoW
Adjuvant durvalumab
ETOP IBCSG Partners Foundation, AstraZeneca AG Switzerland
Non Small Cell Lung Cancer
10/29
03/30
NEMO, NCT02863055 / 2016-000521-38: Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

Active, not recruiting
2
37
Europe
Nintedanib, Placebo
European Organisation for Research and Treatment of Cancer - EORTC
Malignant Pleural Mesothelioma
03/24
03/24
ADEPPT, NCT05673187 / 2022-002736-31: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

Recruiting
2
68
Europe
Adagrasib
ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc.
NSCLC Stage IV, KRAS P.G12C
10/25
03/26
AMAZE-lung, NCT05601973 / 2021-002337-42: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Recruiting
2
60
Europe
Amivantamab, Lazertinib, Zirabev
ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals
Non Small Cell Lung Cancer
03/26
09/26
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC

Withdrawn
2
47
Europe
Sotorasib, Lenvatinib
ETOP IBCSG Partners Foundation, Amgen, Eisai Inc.
Metastatic Non Small Cell Lung Cancer, KRAS G12C
09/26
12/26
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn
2
44
Europe
Brigatinib, Durvalumab
ETOP IBCSG Partners Foundation, Takeda
NSCLC, Stage III, ALK-rearrangement
09/24
09/24
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
POTENT, NCT05782361: - Tepotinib in Combination with Pembrolizumab in NSCLC

Recruiting
1
38
Europe
Tepotinib, Pembrolizumab, MK-3475
Institute of Cancer Research, United Kingdom, Merck Healthcare KGaA
Advanced Cancer, Non Small Cell Lung Cancer
02/28
02/28
NCT01838577: Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

Active, not recruiting
N/A
2000
Europe
European Organisation for Research and Treatment of Cancer - EORTC
EGFR Mutation Positive Non Small Cell Lung Cancer
12/21
03/22
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27

Download Options